OSI Pharmaceuticals Completes its Acquisition of Eyetech Pharmaceuticals
News Nov 15, 2005
OSI acquired Eyetech for approximately $685 million in cash and approximately 5.7 million shares of OSI's common stock.
Net of Eyetech's cash and net operating loss carryforwards, OSI valued the acquisition at approximately $650 million.
Eyetech stockholders will receive $15 per share in cash and 0.12275 of OSI shares for each share of Eyetech owned as of the closing date.
The transaction creates a company that focuses on three therapeutic disease areas of significant market potential: oncology, eye diseases and diabetes, and effectively leverages the Company's core expertise in drug discovery and development.
The Company now has two major marketed products (for the treatment of cancer and age-related macular degeneration) and a product pipeline offering both indications for the marketed products and therapeutics in all three disease areas.
Tarceva® and Macugen® are two of the exciting biotech products launched in recent years.
Tarceva, OSI's flagship product, is approved in the United States for the treatment of advanced non-small cell lung cancer (NSCLC) and pancreatic cancer and approved in the European Union for advanced NSCLC.
Macugen is approved in the United States for the treatment of neovascular age-related macular degeneration and European approval is anticipated by year end.
PhoreMost Completes $15M (£11M) Series-A Round to Enter Drug DiscoveryNews
Investment to fund expansion of operations and progression of drug target pipeline.READ MORE
Abzena Selects Sartorius Stedim Biotech to Equip its US Based Development and Manufacturing SitesNews
Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.READ MORE
Molecule Prevents Common Cold Virus from Hijacking Human CellsNews
Researchers have lab-tested a molecule that can combat the common cold virus by preventing it from hijacking human cells.READ MORE
Comments | 0 ADD COMMENT
9th International Conference on Mass Spectrometry and Chromatography
Sep 21 - Sep 22, 2018